LU92307I2 - Elviégravir sous toutes ses formes comme protégéespar le brevet de base - Google Patents

Elviégravir sous toutes ses formes comme protégéespar le brevet de base

Info

Publication number
LU92307I2
LU92307I2 LU92307C LU92307C LU92307I2 LU 92307 I2 LU92307 I2 LU 92307I2 LU 92307 C LU92307 C LU 92307C LU 92307 C LU92307 C LU 92307C LU 92307 I2 LU92307 I2 LU 92307I2
Authority
LU
Luxembourg
Prior art keywords
elviégravir
protected
forms
basic patent
basic
Prior art date
Application number
LU92307C
Other languages
English (en)
Other versions
LU92307I9 (fr
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32329647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92307(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of LU92307I2 publication Critical patent/LU92307I2/fr
Publication of LU92307I9 publication Critical patent/LU92307I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LU92307C 2002-11-20 2013-11-11 Elviégravir sous toutes ses formes comme protégéespar le brevet de base LU92307I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002336843 2002-11-20
JP2003065807 2003-03-11
JP2003139616 2003-05-16
PCT/JP2003/014773 WO2004046115A1 (fr) 2002-11-20 2003-11-20 Composes 4-oxoquinoliniques et leur utilisation comme inhibiteur de la vih-integrase

Publications (2)

Publication Number Publication Date
LU92307I2 true LU92307I2 (fr) 2014-01-13
LU92307I9 LU92307I9 (fr) 2019-01-17

Family

ID=32329647

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92307C LU92307I2 (fr) 2002-11-20 2013-11-11 Elviégravir sous toutes ses formes comme protégéespar le brevet de base

Country Status (31)

Country Link
US (6) US7176220B2 (fr)
EP (5) EP3406596A1 (fr)
KR (1) KR100665919B1 (fr)
AR (2) AR042095A1 (fr)
AT (1) ATE443048T1 (fr)
AU (1) AU2003302029B8 (fr)
BE (1) BE2013C063I2 (fr)
BR (1) BRPI0306214B1 (fr)
CA (1) CA2470365C (fr)
CY (2) CY1110690T1 (fr)
CZ (1) CZ2004764A3 (fr)
DE (1) DE60329318D1 (fr)
DK (1) DK1564210T5 (fr)
ES (1) ES2329240T3 (fr)
FR (1) FR13C0061I2 (fr)
HU (1) HUS1300066I1 (fr)
IL (2) IL162548A0 (fr)
LT (1) LTPA2013018I1 (fr)
LU (1) LU92307I2 (fr)
MX (1) MXPA04006553A (fr)
MY (1) MY136173A (fr)
NO (3) NO327098B1 (fr)
NZ (1) NZ533641A (fr)
PE (1) PE20040840A1 (fr)
PT (1) PT1564210E (fr)
SI (1) SI1564210T1 (fr)
SK (1) SK2662004A3 (fr)
TR (1) TR200401663T1 (fr)
TW (1) TWI248928B (fr)
WO (1) WO2004046115A1 (fr)
ZA (1) ZA200404537B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1441735B1 (fr) 2001-10-26 2006-02-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Inhibiteurs de l'integrase du vih a base d'hydroxypyrimidinone carboxamide n-substitue
SI1564210T1 (sl) * 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
DE602005023717D1 (de) 2004-03-10 2010-11-04 Usa Chinolin-4-one als inhibitoren der retroviralen integrase zur behandlung von hiv, aids und aids-related complex (arc)
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (fr) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Nouveau composé 4-oxoquinoline et utilisation de celui-ci comme inhibiteur d'intégrase de vih
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
US7745459B2 (en) 2004-09-21 2010-06-29 Japan Tobacco Inc. Quinolizinone compound and use thereof as HIV integrase inhibitor
WO2006033422A1 (fr) * 2004-09-21 2006-03-30 Japan Tobacco Inc. Compose de quinolizinone et utilisation de celui-ci en tant qu'inhibiteur de l'integrase du vih
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US20070032522A1 (en) * 2005-07-01 2007-02-08 Kumar Dange V Antiviral agents
WO2007063869A1 (fr) * 2005-11-30 2007-06-07 Japan Tobacco Inc. Procede de fabrication d’un compose de quinolone de grande purete
EA018544B1 (ru) 2005-12-30 2013-08-30 Джилид Сайэнс, Инк. Способ лечения ретровирусной инфекции
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
JP2009525261A (ja) * 2006-02-01 2009-07-09 日本たばこ産業株式会社 レトロウイルス感染症の治療のための、６−（３−クロロ−２−フルオロベンジル）−１−［（２ｓ）−１−ヒドロキシ−３−メチルブタン−２−イル］−７−メトキシ−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸またはその塩の使用
WO2007092802A1 (fr) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Méthode pour traiter une infection au vih par co-administration de tipranavir et de gs 9137
MX2008011457A (es) 2006-03-06 2008-09-24 Japan Tobacco Inc Metodo para producir un compuesto de 4-oxoquinolina.
CN101437801B (zh) * 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
TW200811153A (en) * 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
RU2399616C1 (ru) * 2006-06-23 2010-09-20 Джапан Тобакко Инк. Производное 6-(гетероциклзамещенный бензил)-4-оксохинолина и его применение в качестве ингибитора интегразы вич
AR061838A1 (es) 2006-07-07 2008-09-24 Gilead Sciences Inc Moduladores de propiedades farmacocineticas de terapeuticos
AU2007275805A1 (en) * 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
CN105503721A (zh) * 2006-09-12 2016-04-20 吉里德科学公司 制备整合酶抑制剂的方法和中间体
NZ575831A (en) 2006-09-29 2011-12-22 Idenix Pharmaceuticals Inc Enantiomerically pure phosphoindoles as hiv inhibitors
DE602007012308D1 (de) 2006-12-22 2011-03-10 Avexa Ltd Bicyclische pyrimidinone und deren verwendung
EP2118082B1 (fr) * 2007-02-23 2014-10-01 Gilead Sciences, Inc. Modulateurs de propriétés pharmacocinétiques de produits thérapeutiques
AU2008270634B2 (en) * 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
CA2692101A1 (fr) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Combinaison d'acide 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-hythoxy-4-oxo-1,4-dihydroquinoleine-3-carboxylique et d'un compose qui inhibe une voie ugt ou un metabolisme ugt
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
WO2009035662A1 (fr) * 2007-09-12 2009-03-19 Concert Pharmaceuticals, Inc. Dérivés deutérés de 4-oxoquinoléine pour le traitement de l'infection par le vih
SI2220076T1 (sl) * 2007-11-15 2012-05-31 Gilead Sciences Inc Inhibitorji replikacije virusa humane imunske pomankljivosti
KR20100097156A (ko) 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
CA2708281A1 (fr) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Inhibiteurs de metalloenzymes utilisant des fractions de liaison a un metal en combinaison avec des fractions de ciblage
US20110166123A1 (en) * 2008-01-07 2011-07-07 Aardea Biosciences, Inc. Novel compositions and methods of use
AP3089A (en) 2008-05-02 2015-01-31 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
WO2010073078A2 (fr) * 2008-12-22 2010-07-01 Orchid Research Laboratories Ltd. Composés hétérocycliques comme inhibiteurs de hdac
BRPI1008664A2 (pt) * 2009-02-06 2016-03-08 Gilead Sciences Inc comprimidos para a terapia de combinação
EP2395983B1 (fr) 2009-02-13 2020-04-08 Boehringer Ingelheim International GmbH Composition pharmaceutique contenant un inhibiteur sglt2 en combinaison avec un inhibiteur dpp-iv et optioenellement un autre agent antidiabetique
WO2010137032A2 (fr) 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Nouvelles formes polymorphes d'elvitégravir et sels pharmaceutiquement acceptables de celui-ci
WO2011004389A2 (fr) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Procédé amélioré pour la préparation d'elvitegravir
US20120220571A1 (en) * 2009-08-26 2012-08-30 Wai John S Hiv integrase inhibitors
SI2486029T1 (sl) 2009-09-30 2015-10-30 Boehringer Ingelheim International Gmbh Postopki za pripravo z glukopiranozilom substituiranih benzil-benzenskih derivatov
EP2483286B1 (fr) 2009-09-30 2016-07-13 Boehringer Ingelheim International GmbH Procédé de préparation d'une forme cristalline de 1-chloro-4-( -d-glucopyranos-1-yl)-2-[4-((s)-tétrahydrofuran-3-yloxy)-benzyl]-benzène
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
ES2446720T3 (es) 2009-10-13 2014-03-10 Elanco Animal Health Ireland Limited Inhibidores de la integrasa macrocíclica
KR20120094098A (ko) 2009-12-07 2012-08-23 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 피리디논 하이드록시사이클로펜틸 카복사미드: 치료 용도의 ｈｉｖ 인테그라제 억제제
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
BR112012033689A2 (pt) 2010-07-02 2019-09-24 Gilead Sciences Inc derivados de ácido 2-quinolinil-acético como compostos de hiv antivirais
SG186820A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht- 2 -ylacetic acid derivatives to treat aids
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
ES2615734T3 (es) 2011-04-21 2017-06-08 Gilead Sciences, Inc. Compuestos de benzotiazol y su uso farmacéutico
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
MX2014005002A (es) 2012-04-20 2014-07-09 Gilead Sciences Inc Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih.
US8877931B2 (en) 2012-08-03 2014-11-04 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CZ304983B6 (cs) 2012-10-12 2015-03-11 Zentiva, K.S. Způsob výroby a nové intermediáty syntézy elvitegraviru
CZ304984B6 (cs) 2012-10-12 2015-03-11 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy elvitegraviru
MX344879B (es) 2012-12-21 2017-01-11 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
US9986714B2 (en) 2012-12-26 2018-06-05 Nestec Sa Low density coated animal litter compositions
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (fr) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
CN113181161A (zh) 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
CZ307255B6 (cs) * 2013-07-11 2018-05-02 Zentiva, K.S. Nový způsob přípravy elvitegraviru
NO2865735T3 (fr) 2013-07-12 2018-07-21
LT3019503T (lt) 2013-07-12 2017-11-27 Gilead Sciences, Inc. Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
NO2717902T3 (fr) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
WO2016081464A1 (fr) * 2014-11-17 2016-05-26 Nirogyone Therapeutics, Inc. Modulateurs de transport des monocarboxylates et leurs utilisations
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CA2980362C (fr) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Composes carbamoylpyridones polycycliques et leur utilisation pharmaceutique
WO2016193997A2 (fr) * 2015-06-03 2016-12-08 Msn Laboratories Private Limited Procédé de préparation d'acide 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-méthylbutan-2-yl]-7-méthoxy-4-oxo-1,4-dihydroquinoline-3-carboxylique et des sels acceptables sur le plan pharmaceutique de celui-ci
RU2729574C2 (ru) 2015-10-23 2020-08-07 Сосьете Де Продюи Нестле С.А. Наполнители низкой плотности для туалетов для домашних животных и способы их получения
RU2654062C2 (ru) * 2016-07-14 2018-05-16 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Производные хиназолин-4(3н)-она, ингибирующие натрий-водородный обмен
MA46742A (fr) 2016-11-10 2019-09-18 Boehringer Ingelheim Int Composition pharmaceutique, méthodes de traitement et leurs utilisations

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS4826772A (fr) 1971-08-11 1973-04-09
DE3501247A1 (de) 1985-01-16 1986-07-17 Bayer Ag, 5090 Leverkusen Aminoacrylsaeure-derivate
US5591744A (en) * 1987-04-16 1997-01-07 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
EP0319906A3 (fr) * 1987-12-11 1990-05-02 Dainippon Pharmaceutical Co., Ltd. Dérivés de la quinoléine, procédé de leur préparation et agent antibactérien les contenant
US4920120A (en) * 1988-01-25 1990-04-24 Warner-Lambert Company Antibacterial agents
DE3934082A1 (de) * 1989-10-12 1991-04-18 Bayer Ag Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel
DE4015299A1 (de) 1990-05-12 1991-11-14 Bayer Ag Verfahren zur herstellung von 3-amino-2-(het)-aroyl-acrylsaeurederivaten
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JPH06199635A (ja) 1992-12-28 1994-07-19 Kanebo Ltd 化粧料
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
WO1995029891A1 (fr) 1994-04-28 1995-11-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de n-(3-pyrrolidinyl)benzamide
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
AU683569B2 (en) * 1994-07-18 1997-11-13 Sankyo Company Limited Trifluoromethylquinolinecarboxylic acid derivative
JPH08183776A (ja) 1994-12-28 1996-07-16 Hideaki Yamaguchi 金属の表面保護剤ならびにそれを用いた製造方法
US6303611B1 (en) * 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
DK0892801T3 (da) 1996-04-12 2002-04-22 Us Gov Health & Human Serv Acridon-afledte forbindelser, der er anvendelige som antineoplastiske og antiretrovirale midler
US6287550B1 (en) * 1996-12-17 2001-09-11 The Procter & Gamble Company Animal care system and litter with reduced malodor impression
US5989451A (en) 1997-02-07 1999-11-23 Queen's University At Kingston Compounds and methods for doping liquid crystal hosts
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
KR20010013377A (fr) * 1997-06-04 2001-02-26 데이비드 엠 모이어 Compositions antimicrobiennes comprenant un analogue de l'acide benzoique et un sel metallique
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
JPH1184556A (ja) 1997-09-08 1999-03-26 Konica Corp ハロゲン化銀乳剤、該乳剤を用いる感光材料の処理方法及び撮影方法
GB9721964D0 (en) * 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
GB9807903D0 (en) 1998-04-14 1998-06-10 Smithkline Beecham Plc Novel compounds
US6399629B1 (en) * 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
DE19950898A1 (de) * 1999-10-22 2001-04-26 Aventis Pharma Gmbh Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
AU2002230392A1 (en) 2000-10-12 2002-05-15 Merck & Co., Inc. AZA-and polyaza-naphthalenyl ketones useful as HIV integrase inhibitors
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
AU2002229057B2 (en) * 2000-12-14 2005-04-21 Warner Chilcott Company, Llc Cyclization process step in the making of quinolones and naphthyridines
WO2002076939A2 (fr) 2001-02-05 2002-10-03 Exegenics Inc. Inhibiteurs de la cysteine protease
MXPA03007765A (es) 2001-03-01 2003-12-08 Shionogi & Co Compuestos heteroarilo que contienen nitrogeno, que tienen actividad inhibitoria contra virus de inmunodeficiencia humana integrasa.
JP4518302B2 (ja) 2001-03-19 2010-08-04 日本化薬株式会社 水溶性ジスアゾ化合物、水性ブラックインク組成物および着色体
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
JP3980842B2 (ja) 2001-05-11 2007-09-26 バブコック日立株式会社 アンモニア含有排水の浄化装置および浄化方法
JP2003065807A (ja) 2001-08-29 2003-03-05 Mitsubishi Electric Corp プロセスデータのトレンド表示方法および装置
JP3913037B2 (ja) 2001-10-30 2007-05-09 三菱電機株式会社 赤外線検出器
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
SI1564210T1 (sl) * 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
JP2004253231A (ja) 2003-02-20 2004-09-09 Pioneer Electronic Corp プラズマディスプレイパネル
WO2005113509A1 (fr) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Nouveau composé 4-oxoquinoline et utilisation de celui-ci comme inhibiteur d'intégrase de vih
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US8633219B2 (en) * 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
MX2008011457A (es) 2006-03-06 2008-09-24 Japan Tobacco Inc Metodo para producir un compuesto de 4-oxoquinolina.
CN101437801B (zh) 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
TW200811153A (en) * 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
CN105503721A (zh) 2006-09-12 2016-04-20 吉里德科学公司 制备整合酶抑制剂的方法和中间体
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
WO2009035662A1 (fr) * 2007-09-12 2009-03-19 Concert Pharmaceuticals, Inc. Dérivés deutérés de 4-oxoquinoléine pour le traitement de l'infection par le vih
US20110166123A1 (en) 2008-01-07 2011-07-07 Aardea Biosciences, Inc. Novel compositions and methods of use
SI23420A (sl) 2010-07-22 2012-01-31 Institut "Jožef Stefan" Kostni vsadki z večslojno prevleko in postopek njihove priprave
US11347056B2 (en) 2018-08-22 2022-05-31 Microsoft Technology Licensing, Llc Foveated color correction to improve color uniformity of head-mounted displays
WO2020040563A1 (fr) 2018-08-23 2020-02-27 엘지이노텍 주식회사 Dispositif de détection
WO2020040561A1 (fr) 2018-08-24 2020-02-27 한온시스템 주식회사 Dispositif de climatisation pour véhicule

Also Published As

Publication number Publication date
DK1564210T5 (da) 2010-05-03
AU2003302029A1 (en) 2004-06-15
US8232401B2 (en) 2012-07-31
EP1564210B9 (fr) 2010-03-31
CZ2004764A3 (cs) 2005-02-16
KR100665919B1 (ko) 2007-03-08
EP1564210A4 (fr) 2007-08-22
US7176220B2 (en) 2007-02-13
SI1564210T1 (sl) 2010-01-29
EP1564210A1 (fr) 2005-08-17
NO20043004L (no) 2004-07-14
EP2161258A3 (fr) 2010-04-07
AU2003302029B8 (en) 2006-08-17
HK1080852A1 (en) 2006-05-04
EP2272516A2 (fr) 2011-01-12
TR200401663T1 (tr) 2005-04-21
MXPA04006553A (es) 2004-10-04
IL162548A (en) 2008-12-29
EP2161258A2 (fr) 2010-03-10
WO2004046115A1 (fr) 2004-06-03
DK1564210T3 (da) 2009-11-16
LU92307I9 (fr) 2019-01-17
BRPI0306214B8 (fr) 2021-05-25
DE60329318D1 (de) 2009-10-29
PT1564210E (pt) 2009-10-26
ATE443048T1 (de) 2009-10-15
NO2022032I1 (no) 2022-07-22
US20150174117A1 (en) 2015-06-25
LTPA2013018I1 (lt) 2022-09-12
NO327098B1 (no) 2009-04-20
SK2662004A3 (sk) 2005-06-02
PE20040840A1 (es) 2004-12-30
CY1110690T1 (el) 2015-06-10
US20060217413A1 (en) 2006-09-28
CA2470365C (fr) 2011-05-17
US20130172344A1 (en) 2013-07-04
BE2013C063I2 (fr) 2023-03-07
NZ533641A (en) 2006-07-28
AR042095A1 (es) 2005-06-08
EP3406596A1 (fr) 2018-11-28
CA2470365A1 (fr) 2004-06-03
BRPI0306214B1 (pt) 2017-08-08
MY136173A (en) 2008-08-29
ES2329240T3 (es) 2009-11-24
AU2003302029B2 (en) 2006-08-10
TW200412339A (en) 2004-07-16
US20230190730A1 (en) 2023-06-22
TWI248928B (en) 2006-02-11
IL162548A0 (en) 2005-11-20
US20050239819A1 (en) 2005-10-27
KR20040081443A (ko) 2004-09-21
EP4059923A1 (fr) 2022-09-21
NO2013015I1 (no) 2013-11-07
NO2013015I2 (no) 2014-06-02
CY2013043I1 (el) 2020-05-29
ZA200404537B (en) 2005-08-31
US20200101061A1 (en) 2020-04-02
BR0306214A (pt) 2004-08-24
FR13C0061I1 (fr) 2013-12-20
EP2272516A3 (fr) 2011-03-16
FR13C0061I2 (fr) 2014-11-07
HUS1300066I1 (hu) 2016-11-28
EP1564210B1 (fr) 2009-09-16
AR087046A2 (es) 2014-02-12

Similar Documents

Publication Publication Date Title
LU92307I2 (fr) Elviégravir sous toutes ses formes comme protégéespar le brevet de base
LU92374I2 (fr) Alogliptin sous toutes ses formes telles que protégées par le brevet de base
LU92327I2 (fr) Ponatinib sous toutes ses formes telles que protégées par le brevet de base
IS7806A (is) Ónæmisvaldandi samsetning
LU92213I2 (fr) Insuline dégludec sous toutes les formes protégéespar le brevet de base
LU92376I2 (fr) Alogliptin sous toutes ses formes telles que protégées par le brevet de base, combiné avec pioglitazone sous toutes ses formes telles que protégées par le brevet de base
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE60325124D1 (de) Arbeitsfahrzeug
FR2862654B1 (fr) Composition amylacee filmogene
DE10393374D2 (de) Zusammensetzung
DE60228702D1 (de) Waschmittelzusammensetzung
IS8387A (is) Ónæmisvaldandi samsetningar
DK1561472T3 (da) Faststofsammensætning
DE60302398D1 (de) Poliervorrichtung
FR2863890B1 (fr) Composition immunostimulante
DE60333528D1 (de) Elektrolytzusammensetzungen
DE602004001733D1 (de) Horizontal-Bearbeitungszentrum
SE0500163L (sv) Sammansättning
DE60217923D1 (de) Weichspülmittel
BR0306184B1 (pt) composição detergente
EP1561467A4 (fr) Composition dermo-reparatrice
ATE404659T1 (de) Waschmittelzusammensetzung
DE60311068D1 (de) Waschmittelzusammensetzung
FR2853526B1 (fr) Support de biberon